北海康成-B(01228)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01228 北海康成-B

未开盘 11-05 15:50:01

1.685

+0.055

+3.37%

最高1.705	最低1.680	成交量15.40万
今开1.680	昨收1.630	日振幅1.53%
总市值10.08亿	流通市值10.08亿	总股本5.98亿
成交额26.08万	换手率0.03%	流通股本5.98亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01228","market":"HK","secType":"STK","nameCN":"北海康成-B","latestPrice":1.685,"timestamp":1793865001117,"preClose":1.63,"halted":0,"volume":154000,"delay":0,"changeRate":0.03374233128834366,"floatShares":598000000,"shares":598000000,"eps":0.03,"marketStatus":"未开盘","change":0.055,"latestTime":"11-05 15:50:01","open":1.68,"high":1.705,"low":1.68,"amount":260825,"amplitude":0.015337,"askPrice":1.745,"askSize":2000,"bidPrice":1.685,"bidSize":8000,"shortable":0,"etf":0,"ttmEps":-0.157,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1793928600000},"marketStatusCode":0,"adr":0,"listingDate":1639065600000,"exchange":"SEHK","adjPreClose":1.63,"openAndCloseTimeList":[[1793842200000,1793851200000],[1793854800000,1793865600000]],"volumeRatio":0.8759954489258271,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01228","defaultTab":"news","newsList":[{"id":"1170966301","title":"北海康成-B 10月无新增发行或股份变动","url":"https://stock-news.laohu8.com/highlight/detail?id=1170966301","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1170966301?lang=zh_cn&edition=full","pubTime":"2026-11-05 16:51","pubTimestamp":1793868677,"startTime":"0","endTime":"0","summary":"北海康成製藥有限公司于2026年11月5日发布的截至2026年10月31日的月报显示，注册股本维持在5,000,000,000股，面值均为每股0.00001美元，总额为50,000美元，与上月保持一致。报告期内，公司已发行股份为597,723,347股，无库藏股份，数量与上月底持平；未见新股发行、股份购回或注销等活动。截至2026年10月底，公司确认符合相关公众持股量要求，股本结构维持稳定。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01228"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142966400","title":"北海康成-B：付钢增持，好仓比例升至18.58%","url":"https://stock-news.laohu8.com/highlight/detail?id=1142966400","media":"港股披露","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1142966400?lang=zh_cn&edition=full","pubTime":"2026-10-30 17:31","pubTimestamp":1793352671,"startTime":"0","endTime":"0","summary":"付钢于2026年10月27日在联交所场内以每股均价1.84港元买入北海康成-B（01228）股份430.00万股，涉资约791.20万港元，属场内主动交易，即在二级市场直接买卖股份。付钢此次增持前持有北海康成-B好仓1.07亿，占比17.86%；增持后持股量为1.11亿，好仓比例升至18.58%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01228"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109628586","title":"北海康成-B：Baheal Wellness Industry International Trading Limited增持，好仓比例升至18.58%","url":"https://stock-news.laohu8.com/highlight/detail?id=1109628586","media":"港股披露","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1109628586?lang=zh_cn&edition=full","pubTime":"2026-10-30 17:23","pubTimestamp":1793352220,"startTime":"0","endTime":"0","summary":"Baheal Wellness Industry International Trading Limited于2026年10月27日在联交所场内以每股均价1.8400港元买入北海康成-B股份430.00万股，涉资约791.20万港元，属场内主动交易，即在二级市场直接买卖股份。Baheal Wellness Industry International Trading Limited此次增持前持有北海康成-B好仓1.07亿，占比17.86%；增持后持股量为1.11亿，好仓比例升至18.58%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01228"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107227466","title":"北海康成-B：北京百洋汇康科技创新发展有限公司增持，好仓比例升至18.58%","url":"https://stock-news.laohu8.com/highlight/detail?id=1107227466","media":"港股披露","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1107227466?lang=zh_cn&edition=full","pubTime":"2026-10-30 17:23","pubTimestamp":1793352216,"startTime":"0","endTime":"0","summary":"北京百洋汇康科技创新发展有限公司于2026年10月27日在联交所场内以每股均价1.84港元买入北海康成-B（01228）股份430.00万股，涉资约791.20万港元。该笔为场内主动交易，属通过联交所公开市场撮合成交的二级市场直接买卖。北京百洋汇康科技创新发展有限公司此次增持前持有北海康成-B好仓1.07亿，占比17.86%；增持后持股量为1.11亿，好仓比例升至18.58%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01228"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187438460","title":"北海康成-B：北京百洋同兴管理谘询有限公司增持，好仓比例升至18.58%","url":"https://stock-news.laohu8.com/highlight/detail?id=1187438460","media":"港股披露","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1187438460?lang=zh_cn&edition=full","pubTime":"2026-10-30 17:16","pubTimestamp":1793351791,"startTime":"0","endTime":"0","summary":"北京百洋同兴管理谘询有限公司于2026年10月27日在联交所场内以每股均价1.84港元买入北海康成-B股份430.00万股，涉资约791.20万港元，属场内主动交易，即在二级市场直接买卖股份。北京百洋同兴管理谘询有限公司此次增持前持有北海康成-B好仓1.07亿，占比17.86%；增持后持股量为1.11亿，好仓比例升至18.58%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01228"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120381922","title":"北海康成-B：Qingdao Baheal Medical Inc.增持，好仓比例升至18.58%","url":"https://stock-news.laohu8.com/highlight/detail?id=1120381922","media":"港股披露","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1120381922?lang=zh_cn&edition=full","pubTime":"2026-10-30 17:15","pubTimestamp":1793351732,"startTime":"0","endTime":"0","summary":"Qingdao Baheal Medical Inc.于2026年10月27日在联交所场内以每股均价1.84港元买入北海康成-B（01228）股份430.00万股，涉资约791.20万港元，属场内主动交易，即在二级市场直接买卖股份。Qingdao Baheal Medical Inc.此次增持前持有北海康成-B好仓1.07亿，占比17.86%；增持后持股量为1.11亿，好仓比例升至18.58%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01228"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112223561","title":"北海康成-B：Baheal Pharma Group Co., Ltd.增持，好仓比例升至18.58%","url":"https://stock-news.laohu8.com/highlight/detail?id=1112223561","media":"港股披露","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1112223561?lang=zh_cn&edition=full","pubTime":"2026-10-30 17:12","pubTimestamp":1793351532,"startTime":"0","endTime":"0","summary":"Baheal Pharma Group Co., Ltd.于2026年10月27日在联交所场内以每股均价1.84港元买入北海康成-B（01228）股份430.00万股，涉资约791.20万港元，属场内主动交易，即在二级市场直接买卖股份。Baheal Pharma Group Co., Ltd.此次增持前持有北海康成-B好仓1.07亿，占比17.86%；增持后持股量为1.11亿，好仓比例升至18.58%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01228"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190215261","title":"北海康成-B公布9月股份变动月报表，股本结构维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1190215261","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1190215261?lang=zh_cn&edition=full","pubTime":"2026-10-06 16:37","pubTimestamp":1791275838,"startTime":"0","endTime":"0","summary":"北海康成制药有限公司于2026年10月6日发布截至2026年9月30日的股份变动月报表。公告显示，公司注册股本总额为50,000美元，股份面值为每股0.00001美元，对应的法定已发行股份总数上限为5,000,000,000股，上述注册股本规模较上月无变化。截至2026年9月末，公司普通股已发行股份合计597,723,347股，库存股份为0股，总计597,723,347股，与上月保持一致。截至本月末，该计划剩余未行使的购股权共19,398,637份，本月并未产生行使期权登记的新股，相关行权所获得的资金数额为0港元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01228"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127681040","title":"北海康成-B2026年中期营收27.9百万元 同比增25.6%，经调整净亏损28.2百万元","url":"https://stock-news.laohu8.com/highlight/detail?id=1127681040","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1127681040?lang=zh_cn&edition=full","pubTime":"2026-09-25 19:56","pubTimestamp":1790337387,"startTime":"0","endTime":"0","summary":"北海康成-B发布2026年中期财报，报告期内营收达27.9百万元，同比增长25.6%。同期经调整净亏损为28.2百万元，较上年同期的37.4百万元收窄9.1百万元。从成本结构看，2026年上半年研发开支为12.5百万元，同比减少30.5%。毛利率录得66.8%，上年同期为69.3%。报告期内，销售及分销开支为30.9百万元，同比上涨36.3%；行政开支达23.3百万元，同比提高40.3%。截至报告期末，经营活动所用现金流量净额为165.19百万元，上年同期为8.83百万元。高管解读暂未在报告中披露。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"北海康成-B2026年中期营收27.9百万元 同比增25.6%，经调整净亏损28.2百万元","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01228"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1163533564","title":"北海康成-B更新2026年8月股份变动月报表，新增280,000股","url":"https://stock-news.laohu8.com/highlight/detail?id=1163533564","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1163533564?lang=zh_cn&edition=full","pubTime":"2026-09-07 16:36","pubTimestamp":1788770195,"startTime":"0","endTime":"0","summary":"北海康成製藥有限公司于2026年9月7日发布截至2026年8月31日的股份变动月报表。北海康成製藥有限公司目前的注册股本维持在5,000,000,000股普通股，每股面值0.00001美元，注册股本总额维持50,000美元。报告期内，公司因首次公开发售后购股权计划共有280,000股普通股被行使并发行。另外，首次公开发售前股权激励计划本月并未发生新股发行或库藏股转让，目前尚有20,643,860股可于该计划项下发行或转让。截至2026年8月31日，发行人股本总数小幅上升至597,723,347股。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01228"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106148116","title":"北海康成-B更新8月股份变动月报，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1106148116","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1106148116?lang=zh_cn&edition=full","pubTime":"2026-09-04 17:16","pubTimestamp":1788513406,"startTime":"0","endTime":"0","summary":"北海康成製藥有限公司于2026年9月4日披露2026年8月股份变动月报。报告显示，截至2026年8月31日，公司注册股本继续保持5,000,000,000股，面值每股0.00001美元，注册股本总额50,000美元未发生变动。上述限制性股份单位所对应股份的实际流通量将根据后续激励计划条款逐步落实。本月未出现新购回或注销股份情形。公司确认已符合适用的香港联交所公众持股量要求，公告由董事长薛群博士签署。公司方面表示将继续遵守香港联交所《上市规则》及相关法律法规。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01228"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663024958","title":"北海康成：上半年亏损3710万元，收入同比增25.6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663024958","media":"财中社","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663024958?lang=zh_cn&edition=full","pubTime":"2026-08-31 12:42","pubTimestamp":1788151320,"startTime":"0","endTime":"0","summary":"8月31日，北海康成（01228）发布中期业绩公告，截止至2026年6月30日止六个月，公司的收益为2790万元，较2025年同期的2220万元增加25.6%。主要增长源自于Hunterase与迈芮倍的销售增长。其他收入及收益大幅减少，从1.04亿元下降至1130万元，主要由于前期美国租赁终止产生的收益减少。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608313859928572.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608313859928572.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["01228","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180975724","title":"北海康成-B2026年中期财报：营收27.9百万元，经调整净利润-28.2百万元","url":"https://stock-news.laohu8.com/highlight/detail?id=1180975724","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1180975724?lang=zh_cn&edition=full","pubTime":"2026-08-31 12:32","pubTimestamp":1788150745,"startTime":"0","endTime":"0","summary":"2026年上半年，北海康成-B实现营收27.9百万元，同比增长25.6%。经调整净利润为-28.2百万元，相比去年同期的-37.4百万元减亏约9.1百万元。毛利率从上年同期的69.3%下降至66.8%。主要成本结构中，研发费用12.5百万元，同比下降30.5%；销售及分销费用30.9百万元，同比上升36.3%；行政开支23.3百万元，同比上升40.3%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"北海康成-B2026年中期财报：营收27.9百万元，经调整净利润-28.2百万元","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01228"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662430066","title":"北海康成-B(01228.HK)发布中期业绩 股东应占亏损3921.8万元 同比盈转亏","url":"https://stock-news.laohu8.com/highlight/detail?id=2662430066","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662430066?lang=zh_cn&edition=full","pubTime":"2026-08-28 17:52","pubTimestamp":1787910751,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","01228"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191858232","title":"北海康成-B（01228）2026年上半年营收27.9百万元，经调整净亏损28.2百万元","url":"https://stock-news.laohu8.com/highlight/detail?id=1191858232","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1191858232?lang=zh_cn&edition=full","pubTime":"2026-08-28 17:36","pubTimestamp":1787909784,"startTime":"0","endTime":"0","summary":"2026年上半年，北海康成-B实现营收27.9百万元，同比增加25.6%。期内经调整净亏损28.2百万元，相较上一年同期的37.4百万元下降24.3%。报告期内毛利为18.7百万元，对应毛利率66.8%。销售及分销开支扩大至30.9百万元，同比上升36.3%，主要投入在戈芮宁的商用推广，以及由自营转为合同销售模式所产生的一次性支出。戈谢病酶替代疗法戈芮宁已识别42名患者，并在40个城市纳入惠民保，覆盖1.75亿人口。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"北海康成-B（01228）2026年上半年营收27.9百万元，经调整净亏损28.2百万元","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01228"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660437004","title":"北海康成-B(01228)：迈芮倍®获台湾健保署核准纳入健保支付","url":"https://stock-news.laohu8.com/highlight/detail?id=2660437004","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660437004?lang=zh_cn&edition=full","pubTime":"2026-08-18 06:34","pubTimestamp":1787006093,"startTime":"0","endTime":"0","summary":"智通财经APP讯，北海康成-B 发布公告，用于治疗阿拉杰里综合征与进行性家族性肝内胆汁淤积症的迈芮倍已获台湾健保署核准纳入健保支付，相关健保支付将于2026年9月1日正式生效。公司认为，迈芮倍是台湾地区首个获批用于治疗ALGS与PFIC的治疗药物，两项适应症同步纳入台湾健保支付，是当地患者的重大利好，也是公司罕见病商业化布局的重要里程碑。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1481114.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01228","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136894414","title":"北海康成-B（01228）“迈芮倍®”纳入台湾健保　覆盖ALGS与PFIC自2026年9月1日起生效","url":"https://stock-news.laohu8.com/highlight/detail?id=1136894414","media":"公告速递","labels":["policyRegulatory","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1136894414?lang=zh_cn&edition=full","pubTime":"2026-08-18 06:16","pubTimestamp":1787004970,"startTime":"0","endTime":"0","summary":"北海康成-B8月18日发布自愿公告称，其产品迈芮倍已获台湾中央健康保险署核准纳入健保支付，适用适应症为阿拉杰里综合征和进行性家族性肝内胆汁淤积症。相关健保支付将于2026年9月1日正式生效。根据公告，迈芮倍已在中国内地、中国香港、美国、欧盟及台湾地区获批，用于治疗不同月龄段ALGS与PFIC患者的胆汁淤积性瘙痒。公司表示，迈芮倍成为台湾地区首个同时覆盖ALGS与PFIC的健保支付药物，为本集团在罕见病商业化布局中取得重要进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01228"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660436595","title":"北海康成－Ｂ(01228.HK)拟8月28日举行董事会会议以批准中期业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=2660436595","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660436595?lang=zh_cn&edition=full","pubTime":"2026-08-17 23:07","pubTimestamp":1786979230,"startTime":"0","endTime":"0","summary":"格隆汇8月17日丨北海康成－Ｂ(01228.HK)宣布，公司将于2026年8月28日(星期五)举行董事会会议，藉以(其中包括)考虑及批准公司及其附属公司截至2026年6月30日止六个月的未经审计中期业绩及其发布。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260817/32337751.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1161","01228"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198777098","title":"北海康成-B（01228）拟于8月28日召开董事会审议2026年中期业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1198777098","media":"公告速递","labels":["conferences","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1198777098?lang=zh_cn&edition=full","pubTime":"2026-08-17 22:31","pubTimestamp":1786977112,"startTime":"0","endTime":"0","summary":"北海康成-B（01228）8月17日在港交所公告称，公司董事会将于2026年8月28日（星期五）召开会议，审议并批准公司及其附属公司截至2026年6月30日止六个月的未经审计中期业绩及其发布事宜。\n公告显示，截至公告日期，公司董事会成员包括：执行董事薛群博士；非执行董事赵玮女士、王廷伟先生；以及独立非执行董事Dr. Richard Arthur Moscicki、James Arthur Geraghty、陈炳钧先生及胡澜博士。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01228"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105365375","title":"北海康成-B 2026年7月股份变动月报表：股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1105365375","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1105365375?lang=zh_cn&edition=full","pubTime":"2026-08-06 16:41","pubTimestamp":1786005698,"startTime":"0","endTime":"0","summary":"2026年8月6日，北海康成製藥有限公司公布截至2026年7月31日止月份的证券变动月报表。公告显示，公司本月未新增发行、购回或注销股份，股本结构整体维持稳定。报告期内的法定/注册股本维持在5,000,000,000股，面值为每股0.00001美元，注册股本总额约为50,000美元。根据公告，北海康成-B的首次公开发售后购股权计划在月末结存的股份期权数量为19,798,637份。北海康成-B表示将继续严格遵守香港联交所《上市规则》及其他相关法规规定。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01228"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ssitimber.com.hk","stockEarnings":[{"period":"1week","weight":-0.0534},{"period":"1month","weight":-0.1575},{"period":"3month","weight":-0.2593},{"period":"6month","weight":-0.2674},{"period":"1year","weight":-0.1403},{"period":"ytd","weight":-0.3418}],"compareEarnings":[{"period":"1week","weight":0.0801},{"period":"1month","weight":0.0213},{"period":"3month","weight":-0.0339},{"period":"6month","weight":-0.0605},{"period":"1year","weight":-0.0439},{"period":"ytd","weight":-0.0325}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"CANbridge Pharmaceuticals Inc是一家全球生物制药公司。该公司专注于罕见病转化疗法的研究、开发和商业化。该公司拥有一个药物组合，其中包括三种获批药物和八种资产的管线，针对尚未满足需求的罕见病适应症。这些包括亨特综合征和其他溶酶体贮积症、阵发性睡眠性血红蛋白尿和其他补体介导的疾病、血友病A、代谢性疾病、罕见胆汁淤积性肝病和神经肌肉疾病。其管线包括Hunterase、Livmarli、CAN106和CAN103。Hunterase是一种酶替代疗法，用于治疗II型粘多糖贮积症（MPS II），也称为亨特综合征。Livmarli是一种口服、吸收率极低、可逆性的回肠胆汁酸转运蛋白抑制剂，正在开发中，用于治疗罕见的胆汁淤积性肝病，包括Alagille综合征和进行性家族性肝内胆汁淤积症。","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.126185},{"month":2,"riseRate":0.4,"avgChangeRate":0.011895},{"month":3,"riseRate":0.2,"avgChangeRate":-0.095239},{"month":4,"riseRate":0.2,"avgChangeRate":-0.054254},{"month":5,"riseRate":0,"avgChangeRate":-0.09989},{"month":6,"riseRate":0.4,"avgChangeRate":0.271134},{"month":7,"riseRate":0.4,"avgChangeRate":0.385009},{"month":8,"riseRate":0.2,"avgChangeRate":0.187363},{"month":9,"riseRate":0.8,"avgChangeRate":0.159031},{"month":10,"riseRate":0,"avgChangeRate":-0.17111},{"month":11,"riseRate":0.2,"avgChangeRate":-0.174215},{"month":12,"riseRate":0.5,"avgChangeRate":0.059277}],"exchange":"SEHK","name":"北海康成-B","nameEN":"CANBRIDGE-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"北海康成-B(01228)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供北海康成-B(01228)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"北海康成-B,01228,北海康成-B股票,北海康成-B股票老虎,北海康成-B股票老虎国际,北海康成-B行情,北海康成-B股票行情,北海康成-B股价,北海康成-B股市,北海康成-B股票价格,北海康成-B股票交易,北海康成-B股票购买,北海康成-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"北海康成-B(01228)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供北海康成-B(01228)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}